Moderna Inc. diskutieren

Moderna, Inc. (NASDAQ: MRNA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $214.00 price target on the stock.

Moderna, Inc. (NASDAQ: MRNA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock, down previously from $214.00.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $168.00 to $155.00. They now have an "overweight" rating on the stock.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $204.00 to $178.00. They now have a "buy" rating on the stock.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Royal Bank of Canada from $160.00 to $125.00. They now have an "outperform" rating on the stock.

Moderna's looking a bit under the weather, folks. Analysts are giving it the cold shoulder, slashing revenue forecasts by a whopping 35% for 2024. Ouch! That's like expecting a marathon runner to suddenly start crawling. With the COVID vaccine party winding down, Moderna's struggling to find its next big hit. Sure, they've got some irons in the fire with RSV and flu vaccines, but it's no slam dunk. The stock's been on a rollercoaster ride, and right now, it feels like we're heading for a steep drop. Don't get me wrong, Moderna's got brains in spades, but in this market, that might not be enough to keep the ship afloat. It's like they're trying to sell sunscreen in winter – tough sell, right? With big players like RBC Capital Markets downgrading them, it might be time to grab your life vest. Remember, in the biotech world, you're only as good as your next breakthrough. So, unless Moderna pulls a rabbit out of its hat soon, I'd be tempted to jump ship before the storm hits.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Piper Sandler from $157.00 to $115.00. They now have an "overweight" rating on the stock.

Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. They now have a $70.00 price target on the stock, down previously from $88.00.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $155.00 to $125.00. They now have an "overweight" rating on the stock.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $178.00 to $139.00. They now have a "buy" rating on the stock.

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Leerink Partners from $60.00 to $48.00. They now have an "underperform" rating on the stock.